Skip to main content

Table 1 Baseline characteristics of the sample

From: Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

  Total samplea (n = 169) Early-phase (n = 108) Later-phase (n = 59)
Male gender, n (%) 114 (67.5%) 75 (69.4%) 38 (64.4%)
Age at consent (years), mean (SD) 32.9 (12.2) 28.0 (9.4) 41.6 (11.9)
AOM mean dose (mg), mean (SD) 371.6 (50.2) 371.3 (53.0) 371.2 (45.7)
GAF score, mean (SD) 48.7 (12.6) 49.1 (13.6) 48.5 (10.6)
SOFAS score, mean (SD) 50.1 (12.3) 50.5 (13.0) 49.9 (11.0)
CGI-S score, mean (SD) 4.0 (0.8) 4.0 (0.9) 4.1 (0.6)
BPRS score, mean (SD) 39.8 (11.3) 39.8 (12.7) 39.6 (8.2)
  1. aAt enrollment, 2 patients could not be characterized as early or later phase